VEOZAH®

Hold Company

ASTELLAS

Learn More

Dosage and Administration

TABLET;ORAL

Specification

45MG

Indication

Veozah® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Use

Instructions for Use

API

FEZOLINETANT

API Structure

We Supply

FEZOLINETANT

Drug Patent

Patent No	Expiration Date
10836768	2034/3/28
8871761	2031/4/4
9422299	2034/3/28
9987274	2034/3/28

API Patent

Patent No	Expiration Date
10836768	2034/3/28
8871761	2031/4/4
9422299	2034/3/28
9987274	2034/3/28

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.